bioMerieux (FR:BIM) has released an update.
bioMerieux has announced FDA authorization and CLIA waiver for its BIOFIRE SPOTFIRE R/ST Panel Mini, enhancing the ‘Point of Care’ market with rapid, sensitive testing for common respiratory viruses and streptococcal infections. This test, which provides results in about 15 minutes from a single sample, is set to be available in the U.S. from Q3 2024. It represents a significant advancement in delivering quick, accurate diagnoses and appropriate treatments at patient care sites.
For further insights into FR:BIM stock, check out TipRanks’ Stock Analysis page.
